With funding, resources, and collaboration, experts can improve their analysis and help patients. How are ECOG-ACRIN and Caris Life Sciences teaming up to fight cancer? Their recent announcement will ...

此次获批主要基于III期MIRASOL 试验，2024年欧洲肿瘤内科学会（ESMO）上报告了该试验结果。共227例患者接受索米妥昔单抗，226例患者接受对照组治疗，结果显示：索米妥昔单抗组有97例患者肿瘤缩小或消失，其中13例患者达到完全缓解（CR） ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Innovative e-tattoo neurotech that prints directly on the scalp may be a game-changer for precision medicine, neuroscience, ...

Fenske, MD led ECOG-ACRIN EA4151, the first randomized trial to compare treatment with or without stem cell transplant in patients with MRD-negative mantle cell lymphoma in first complete remission.

Annual Meeting & Exposition provides insights into the prognostic utility of geriatric assessment tools and their role in ...

Large research symposium highlights liquid biopsies, new drug combos, shifts in surgical practice and, yes, patient voices.

The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated ...

venetoclax (Venclexta) plus rituximab (Rituxan) Completed 24-month treatment regimen Was in treatment-free interval for 6 months Due to disease progression, his hemoglobin has dropped over the past 3 ...

Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses ...

The new study—led by the University of Exeter and Institute of Biodiversity and Protected Areas (IBAP) of ...